Mirum Pharmaceuticals Inc. (MIRM)
Mirum's Q2 Earnings Lag Estimates, Revenues Beat, 2026 View Raised
MIRM Q2 earnings miss estimates while revenues beat the same, as Livmarli and bile acid drugs fuel growth, prompting a higher 2026 sales outlook.
Mirum Pharmaceuticals, Inc. (MIRM) Q2 2026 Earnings Call Transcript
Mirum Pharmaceuticals, Inc. (MIRM) Q2 2026 Earnings Call Transcript
Mirum Pharmaceuticals Q2 Earnings Call Highlights
Mirum Pharmaceuticals NASDAQ: MIRM reported second-quarter net product sales of $176 million and raised its full-year 2026 product sales outlook to $680 million to $700 million, while outlining several upcoming clinical and regulatory milestones across its rare liver and rare genetic disease portfolios.
Compared to Estimates, Mirum Pharmaceuticals (MIRM) Q2 Earnings: A Look at Key Metrics
The headline numbers for Mirum Pharmaceuticals (MIRM) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q2 Loss, Beats Revenue Estimates
Mirum Pharmaceuticals, Inc. (MIRM) came out with a quarterly loss of $0.8 per share versus the Zacks Consensus Estimate of a loss of $0.77. This compares to a loss of $0.12 per share a year ago.
Mirum Pharmaceuticals: This Liver Disease Juggernaut Just Broadened Its Portfolio
Mirum Pharmaceuticals is evolving into a leading liver disease franchise, with robust revenue growth and a diversified pipeline targeting high-value indications. MIRM raised its 2026 global sales guidance to $660–$680 million, supported by strong LIVMARLI performance. Recent acquisitions have delayed cash flow positivity to 2028, but the company's pipeline—Volixibat, MRM-3379, and Brelovitug—offers multiple blockbuster opportunities.
Strength Seen in Mirum Pharmaceuticals (MIRM): Can Its 5.5% Jump Turn into More Strength?
Mirum Pharmaceuticals (MIRM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review (Revised)
Mirum and Incyte's zilurgisertib cut new bone lesion formation in rare disease FOP, as the FDA begins Priority Review of the NDA with a Sept. 26, 2026, decision date.
MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review (Revised)
Mirum and Incyte's zilurgisertib cut new bone lesion formation in rare disease FOP, as the FDA begins Priority Review of the NDA with a Sept. 26, 2026, decision date.
MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review
Mirum and Incyte's zilurgisertib cut new bone lesion formation in rare disease FOP, as the FDA begins Priority Review of the NDA with a Sept. 26, 2026, decision date.
Why Is Mirum Pharmaceuticals (MIRM) Down 10.1% Since Last Earnings Report?
Mirum Pharmaceuticals (MIRM) reported earnings 30 days ago. What's next for the stock?
Mirum Pharmaceuticals Enters Catalyst-Rich Stretch as LIVMARLI Sales and Pipeline Advance
Mirum Pharmaceuticals NASDAQ: MIRM executives said the rare disease company is entering a catalyst-heavy period, with recent positive clinical updates, ongoing commercial momentum for LIVMARLI and additional business development activity expanding its portfolio.
